Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras

Molecular Cell

Volumn 44, Issue 6, 2011, Pages 893-906

  Matallanas, David ^a   Romano, David ^a   Al Mulla, Fahd ^b   O'Neill, Eric ^c   Al Ali, Waleed ^b   Crespo, Piero ^d   Doyle, Brendan ^e   Nixon, Colin ^e   Sansom, Owen ^e   Drosten, Matthias ^f   Barbacid, Mariano ^f   Kolch, Walter ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b KUWAIT UNIVERSITY   (Kuwait)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d University of Cantabria   (Spain)

^e BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^f Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; LATS1 PROTEIN; MST2 PROTEIN; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; WILD TYPE;

ALLELES; ANIMALS; APOPTOSIS; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MICE; MUTANT PROTEINS; MUTATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84255187573     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2011.10.016     Document Type: Article

References (57)

1. Agathanggelou A., Cooper W.N., Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005, 65:3497-3508.
2. Al-Mulla F., Going J.J., Sowden E.T., Winter A., Pickford I.R., Birnie G.D. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J. Pathol. 1998, 185:130-138.
3. Al-Mulla F., Hagan S., Behbehani A.I., Bitar M.S., George S.S., Going J.J., García J.J., Scott L., Fyfe N., Murray G.I., Kolch W. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J. Clin. Oncol. 2006, 24:5672-5679.
4. Amit I., Citri A., Shay T., Lu Y., Katz M., Zhang F., Tarcic G., Siwak D., Lahad J., Jacob-Hirsch J., et al. A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 2007, 39:503-512.
5. Avruch J., Xavier R., Bardeesy N., Zhang X.F., Praskova M., Zhou D., Xia F. Rassf family of tumor suppressor polypeptides. J. Biol. Chem. 2009, 284:11001-11005.
6. Aylon Y., Michael D., Shmueli A., Yabuta N., Nojima H., Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev. 2006, 20:2687-2700.
7. Barbacid M. ras genes. Annu. Rev. Biochem. 1987, 56:779-827.
8. Benlloch S., Payá A., Alenda C., Bessa X., Andreu M., Jover R., Castells A., Llor X., Aranda F.I., Massutí B. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J. Mol. Diagn. 2006, 8:540-543.
9. Bivona T.G., Quatela S.E., Bodemann B.O., Ahearn I.M., Soskis M.J., Mor A., Miura J., Wiener H.H., Wright L., Saba S.G., et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 2006, 21:481-493.
10. Buday L., Downward J. Many faces of Ras activation. Biochim. Biophys. Acta 2008, 1786:178-187.
11. Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 1993, 13:4107-4114.
12. Cox A.D., Der C.J. The dark side of Ras: regulation of apoptosis. Oncogene 2003, 22:8999-9006.
13. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
14. Donninger H., Vos M.D., Clark G.J. The RASSF1A tumor suppressor. J. Cell Sci. 2007, 120:3163-3172.
15. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
16. Drosten M., Dhawahir A., Sum E.Y., Urosevic J., Lechuga C.G., Esteban L.M., Castellano E., Guerra C., Santos E., Barbacid M. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 2010, 29:1091-1104.
17. Gangarosa L.M., Sizemore N., Graves-Deal R., Oldham S.M., Der C.J., Coffey R.J. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J. Biol. Chem. 1997, 272:18926-18931.
18. Haigis K.M., Kendall K.R., Wang Y., Cheung A., Haigis M.C., Glickman J.N., Niwa-Kawakita M., Sweet-Cordero A., Sebolt-Leopold J., Shannon K.M., et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 2008, 40:600-608.
19. Hamilton G., Yee K.S., Scrace S., O'Neill E. ATM regulates a RASSF1A-dependent DNA damage response. Curr. Biol. 2009, 19:2020-2025.
20. Hegymegi-Barakonyi B., Eros D., Szántai-Kis C., Breza N., Bánhegyi P., Szabó G.V., Várkondi E., Peták I., Orfi L., Kéri G. Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. Curr. Opin. Mol. Ther. 2009, 11:308-321.
21. Holgren C., Dougherty U., Edwin F., Cerasi D., Taylor I., Fichera A., Joseph L., Bissonnette M., Khare S. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene 2010, 29:5241-5253.
22. Johnson D.G., Degregori J. Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context. Curr. Mol. Med. 2006, 6:731-738.
23. Johnston P.G. Stage II colorectal cancer: to treat or not to treat. Oncologist 2005, 10:332-334.
24. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9:517-531.
25. Khokhlatchev A., Rabizadeh S., Xavier R., Nedwidek M., Chen T., Zhang X.F., Seed B., Avruch J. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 2002, 12:253-265.
26. Kreeger P.K., Mandhana R., Alford S.K., Haigis K.M., Lauffenburger D.A. RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. Cancer Res. 2009, 69:8191-8199.
27. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., Papadimitriou C.A., Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9:962-972.
28. Liu X., Jakubowski M., Hunt J.L. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am. J. Clin. Pathol. 2011, 135:245-252.
29. Lu L., Li Y., Kim S.M., Bossuyt W., Liu P., Qiu Q., Wang Y., Halder G., Finegold M.J., Lee J.S., Johnson R.L. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. USA 2010, 107:1437-1442.
30. Malumbres M., Pellicer A. RAS pathways to cell cycle control and cell transformation. Front. Biosci. 1998, 3:d887-d912.
31. Matallanas D., Arozarena I., Berciano M.T., Aaronson D.S., Pellicer A., Lafarga M., Crespo P. Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J. Biol. Chem. 2003, 278:4572-4581.
32. Matallanas D., Romano D., Yee K., Meissl K., Kucerova L., Piazzolla D., Baccarini M., Vass J.K., Kolch W., O'neill E. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell 2007, 27:962-975.
33. Matallanas D., Romano D., Hamilton G., Kolch W., O'Neill E. A Hippo in the ointment: MST signalling beyond the fly. Cell Cycle 2008, 7:879-884.
34. Minoo P., Zlobec I., Baker K., Tornillo L., Terracciano L., Jass J.R., Lugli A. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod. Pathol. 2007, 20:331-338.
35. Morton J.P., Timpson P., Karim S.A., Ridgway R.A., Athineos D., Doyle B., Jamieson N.B., Oien K.A., Lowy A.M., Brunton V.G., et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2010, 107:246-251.
36. Normanno N., Tejpar S., Morgillo F., De Luca A., Van Cutsem E., Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 2009, 6:519-527.
37. O'Connell A.R., Stenson-Cox C. A more serine way to die: defining the characteristics of serine protease-mediated cell death cascades. Biochim. Biophys. Acta 2007, 1773:1491-1499.
38. O'Neill E., Rushworth L., Baccarini M., Kolch W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 2004, 306:2267-2270.
39. Ogino S., Meyerhardt J.A., Cantor M., Brahmandam M., Clark J.W., Namgyal C., Kawasaki T., Kinsella K., Michelini A.L., Enzinger P.C., et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin. Cancer Res. 2005, 11:6650-6656.
40. Ortiz-Vega S., Khokhlatchev A., Nedwidek M., Zhang X.F., Dammann R., Pfeifer G.P., Avruch J. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002, 21:1381-1390.
41. Pardali K., Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim. Biophys. Acta 2007, 1775:21-62.
42. Pollock C.B., Shirasawa S., Sasazuki T., Kolch W., Dhillon A.S. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res. 2005, 65:1244-1250.
43. Puyol M., Martín A., Dubus P., Mulero F., Pizcueta P., Khan G., Guerra C., Santamaría D., Barbacid M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
44. Richter A.M., Pfeifer G.P., Dammann R.H. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim. Biophys. Acta 2009, 1796:114-128.
45. Romano D., Matallanas D., Weitsman G., Preisinger C., Ng T., Kolch W. Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 2010, 70:1195-1203.
46. Shaw A.T., Meissner A., Dowdle J.A., Crowley D., Magendantz M., Ouyang C., Parisi T., Rajagopal J., Blank L.J., Bronson R.T., et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev. 2007, 21:694-707.
47. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
48. Siena S., Sartore-Bianchi A., Di Nicolantonio F., Balfour J., Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 2009, 101:1308-1324.
49. Solca F.F., Baum A., Langkopf E., Dahmann G., Heider K.H., Himmelsbach F., van Meel J.C. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J. Pharmacol. Exp. Ther. 2004, 311:502-509.
50. Stieglitz B., Bee C., Schwarz D., Yildiz O., Moshnikova A., Khokhlatchev A., Herrmann C. Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J. 2008, 27:1995-2005.
51. Takayama T., Katsuki S., Takahashi Y., Ohi M., Nojiri S., Sakamaki S., Kato J., Kogawa K., Miyake H., Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med. 1998, 339:1277-1284.
52. To M.D., Perez-Losada J., Mao J.H., Hsu J., Jacks T., Balmain A. A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat. Genet. 2006, 38:926-930.
53. Wade M., Wang Y.V., Wahl G.M. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010, 20:299-309.
54. Watanabe M., Nobuta A., Tanaka J., Asaka M. An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int. J. Cancer 1996, 67:264-268.
55. Yuan M., Tomlinson V., Lara R., Holliday D., Chelala C., Harada T., Gangeswaran R., Manson-Bishop C., Smith P., Danovi S.A., et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 2008, 15:1752-1759.
56. Zhang Z., Wang Y., Vikis H.G., Johnson L., Liu G., Li J., Anderson M.W., Sills R.C., Hong H.L., Devereux T.R., et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 2001, 29:25-33.
57. Zhou D., Conrad C., Xia F., Park J.S., Payer B., Yin Y., Lauwers G.Y., Thasler W., Lee J.T., Avruch J., Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009, 16:425-438.